This was the Chinese study:
After one month, it appeared 13.9% of the remdesivir patients had died compared to 12.8% of patients in the control arm. The difference was not statistically significant.
https://www.statnews.com/2020/04/23/data-on-gileads-remdesivir-released-by-accident-show-no-benefit-for-coronavirus-patients/
More and more important that ATH gets to the COVID race.
Remdesivir, no benefit for COVID- patients
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $18.45K | 6.153M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 66 | 112553933 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 140078273 | 50 |
View Market Depth
| Last trade - 11.42am 18/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |